Why the World Stopped Sleeping — and How a Booming Industry Is Finally Taking It Seriously

The Great Sleep Collapse

Americans sleep an average of 6.8 hours per night, down from 7.9 hours in 1942 according to Gallup tracking data — a reduction of over an hour per night in less than a century, representing one of the largest behavioral shifts in modern public health history. The United Kingdom's sleep average sits at 6.4 hours. Japan, with its concept of 'inemuri' (sleeping in public) as a badge of dedication, averages 6.3 hours. South Korea clocks in at 6.3 hours as well. The CDC classifies less than 7 hours as insufficient for adult health; by that standard, the majority of the working population of the developed world is chronically underslept, every single night.

The causes of this collapse are intertwined and mutually reinforcing in ways that make simple solutions difficult to implement. The electrification of the night and the shift to artificial lighting disrupted circadian rhythms by extending the light-saturated day deep into the hours when human biology expects darkness and the initiation of melatonin secretion. The globalization of work extended the psychological workspace around the clock, particularly for knowledge workers whose work arrives via a device they carry everywhere and check compulsively before bed. Social media and streaming platforms have monetized 'second screen' nighttime entertainment with precisely calibrated algorithmic engagement that keeps users scrolling at the exact hours when they should be asleep. And in a culture that has historically valorized busyness and sleep deprivation as markers of commitment and ambition — 'I'll sleep when I'm dead' as Silicon Valley's unofficial motto — the social permission structures that would otherwise protect sleep have been systematically dismantled. A growing slow tech movement has emerged partly in direct response — deliberately stepping back from always-on devices to reclaim rest and attention.

The cost of this experiment is now arriving in the data. Sleep deprivation is not merely inconvenient; it is medically catastrophic at both individual and population scale. The science connecting insufficient sleep to cardiovascular disease, metabolic dysfunction, immune suppression, cognitive decline, and mental health deterioration has hardened considerably over the past decade, shifting sleep medicine from a specialty concern to a mainstream public health priority. Matthew Walker's 2017 book 'Why We Sleep,' which synthesized a generation of sleep research for popular audiences, was a cultural moment: it made visible the scale of a crisis that had been building in plain sight for decades.

What Sleep Deprivation Actually Does to the Body and Brain

The physiological consequences of chronic sleep restriction are profound and affect virtually every organ system in the human body. The cardiovascular system is among the most severely affected. Large epidemiological studies have consistently found that sleeping fewer than six hours per night is associated with 20 to 45 percent increases in the risk of cardiovascular disease, stroke, and hypertension relative to those sleeping seven to eight hours. The mechanisms are multiple: sleep deprivation elevates systemic inflammation markers including C-reactive protein and interleukin-6, impairs endothelial function and vascular repair processes that occur preferentially during sleep, and dysregulates the autonomic nervous system in ways that increase blood pressure and heart rate variability.

Metabolic effects are equally well documented. Even modest sleep restriction — reducing sleep from eight to five hours for a single week in otherwise healthy subjects — produces measurable insulin resistance, impairs glucose regulation, and alters the balance of hormones regulating appetite in ways that increase caloric intake and drive toward high-calorie foods. Ghrelin, the hormone that stimulates hunger, rises with sleep loss; leptin, which signals satiety, falls. The practical result is that chronically underslept individuals consume approximately 300 to 500 additional calories per day compared to their well-rested counterparts in controlled laboratory settings, a dietary pattern that, sustained over years, substantially increases obesity risk. The connection between the obesity epidemic and the parallel collapse in average sleep duration is not coincidental, though establishing causal weight versus confounding variables remains an active area of research.

Cognitive effects are perhaps the most immediately apparent to individuals, though chronic sleep deprivation has the insidious quality of impairing the metacognitive awareness needed to recognize how impaired one is. Studies measuring reaction time, working memory, decision-making quality, and emotional regulation all show significant degradation with even modest sleep restriction that compounds over successive nights without complete recovery. Crucially, subjective assessments of alertness and impairment diverge sharply from objective performance measures after several nights of insufficient sleep — subjects feel less impaired than they are, partly explaining why chronically underslept individuals frequently underestimate their cognitive deficits. The implications for workplaces, highways, and hospitals, where cognitively impaired decision-making has direct safety consequences, are well-documented and concerning.

The Wearable Revolution and What It Has Taught Us

The proliferation of consumer sleep-tracking devices over the past decade has produced a paradox: never in human history have so many people had access to objective data about their own sleep architecture, and yet sleep quality across the tracked population has not meaningfully improved. The Oura Ring, which monitors heart rate variability, skin temperature, and movement to estimate sleep stages, has sold over 2.5 million units as of 2024. WHOOP, the performance-focused biometric tracker favored by elite athletes and increasingly by knowledge workers, tracks similar metrics and has built a community of over 1 million subscribers. Apple Watch Series 9 and 10 include sleep stage detection. Fitbit and Garmin devices capture sleep data for tens of millions of users nightly. The aggregate dataset that these devices are generating represents the largest observational study of human sleep behavior ever conducted.

The scientific value of this data is genuine and growing. Population-level analyses of Fitbit and Oura data have confirmed sleep patterns across age, gender, geography, and season that validate laboratory findings and reveal new patterns at scale. Research published using WHOOP data has identified recovery-sleep relationships that help explain why elite athletic performance deteriorates after multi-game travel schedules. The correlation between HRV (heart rate variability), a key output metric from wearable sleep trackers, and autonomic nervous system recovery has been sufficiently validated that several cardiology research programs now use consumer wearables as supplementary data collection tools.

For individual users, the value is more complicated. For a significant fraction of users, particularly those who had no prior awareness of their sleep patterns, wearable data produces genuine behavioral change — they discover that alcohol, even in moderate quantities, dramatically suppresses REM sleep; that consistent sleep and wake times improve deep sleep duration; that pre-sleep screen exposure delays sleep onset measurably. For others, however, the obsessive monitoring of sleep metrics produces what sleep researchers have termed 'orthosomnia' — anxiety about achieving perfect sleep scores that paradoxically worsens the very sleep quality being measured. The irony of a device designed to improve sleep creating sleep anxiety in a subset of users is not lost on clinicians, and it points to a genuine design challenge for the next generation of sleep technology: providing actionable insight without triggering the performance anxiety that undermines sleep's fundamentally unconscious, physiologically self-regulating nature.

CBT-I: The Therapy That Works, and Almost Nobody Knows About It

Cognitive Behavioral Therapy for Insomnia, abbreviated CBT-I, is the most effective treatment available for chronic insomnia — more effective than any sleeping medication in head-to-head trials, with durable results that persist after treatment ends, without the dependency, tolerance, and cognitive side effects that accompany pharmacological approaches. The American Academy of Sleep Medicine and the American College of Physicians both recommend CBT-I as the first-line treatment for chronic insomnia. The clinical evidence base is robust: meta-analyses consistently show CBT-I reduces the time to fall asleep, decreases nighttime waking, improves overall sleep quality, and reduces daytime impairment, with effect sizes that are clinically significant.

Despite this evidence base, CBT-I remains dramatically underutilized. Most primary care physicians receive little to no training in sleep medicine and default to prescribing benzodiazepines, Z-drugs (zolpidem, eszopiclone), or over-the-counter antihistamines — all of which provide short-term symptom relief while doing nothing to address the behavioral and cognitive patterns that maintain chronic insomnia, and all of which carry meaningful side-effect profiles including next-day cognitive impairment, falls risk in older adults, and dependency. The shortage of trained CBT-I therapists, the cost of weekly therapy sessions, and simple clinical inertia have maintained this gap between evidence and practice for decades.

Digital CBT-I is emerging as the most promising path to closing this gap at population scale. Programs including Sleepio, Somryst (FDA-cleared as a prescription digital therapeutic), and Insomnia Coach (free, developed by the VA for veterans) deliver the core components of CBT-I — sleep restriction therapy, stimulus control, cognitive restructuring, sleep hygiene education, and relaxation training — through smartphone interfaces that can reach patients anywhere, anytime, at a fraction of the cost of therapist-delivered treatment. Clinical trials of digital CBT-I have shown efficacy comparable to therapist-delivered treatment on the primary outcome measures that matter: improvements in sleep efficiency, insomnia severity index scores, and daytime functioning. The potential scale is significant: an estimated 30 percent of adults experience chronic insomnia symptoms, and the penetration of effective treatment in this population remains below 10 percent by most estimates.

The Business of Better Sleep: A $100 Billion Market Nobody Built for Outcomes

The global sleep economy is frequently cited at figures between $50 billion and $150 billion, depending on the categories included — mattresses and bedding, sleep technology, pharmacological sleep aids, supplements, clinics, apps, and the broader category of sleep-adjacent wellness products. The range illustrates the definitional ambiguity, but the scale is unambiguous: this is one of the largest consumer health markets in the world, and it has grown rapidly over the past decade as sleep moved from personal inconvenience to public health priority.

The product category that has attracted the most investment and media attention is smart mattresses and sleep environment technology. Companies including Eight Sleep, whose Pod mattress system uses water-based temperature regulation controlled by an AI model that learns individual thermal preferences, have attracted premium valuations and high-profile investors on the thesis that sleep environment optimization produces measurable sleep quality improvement. Eight Sleep's published internal data shows users achieving higher sleep scores and faster recovery metrics after adopting temperature optimization, claims that the company argues are supported by its own population-level dataset. Independent clinical validation of these claims remains limited, which is a genuine limitation of the category overall.

The supplements market — melatonin, magnesium glycinate, L-theanine, ashwagandha, and dozens of proprietary blends — represents the largest single category by revenue but also the most scientifically variable. Melatonin has genuine evidence for circadian rhythm shifting in jet lag and shift work contexts, but its efficacy for chronic insomnia is modest and its widespread use at doses far exceeding physiological levels has raised questions about long-term effects that remain insufficiently studied. The broader supplement category benefits from low regulatory barriers and consumer willingness to try inexpensive interventions, but clinical evidence for most products is thin.

The most consequential long-term development in the sleep economy is likely the integration of sleep data with broader healthcare systems. As wearable sleep tracking generates longitudinal records at scale, the ability to identify individuals at risk for sleep-related cardiovascular or metabolic events before symptoms appear represents a genuine clinical opportunity. Insurance companies and employers are beginning to recognize that poor sleep quality in their covered populations produces measurable costs in healthcare utilization, disability, and productivity, creating financial incentives for investment in sleep improvement at population scale. The sleep economy's future is probably less about premium mattresses and more about the integration of sleep as a managed health outcome — measured, intervened upon, and tracked with the same clinical rigor applied to blood pressure or cholesterol. That transition will take time, but the direction is becoming clear.